Q-omics provides the consensus-scored MRPL20-DT profile across patient tissues and cancer cell-line models. MRPL20-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRPL20-DT is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, MRPL20-DT RNA expression shows 18,399 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where MRPL20-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL20-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL20-DT survival associations across molecular data types. MRPL20-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL20-DT RNA expression–survival associations across cancer types. High MRPL20-DT expression shows unfavorable associations in KIRC, ACC, UCEC, LGG and BRCA, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MRPL20-DT RNA expression.
This table summarizes MRPL20-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MRPL20-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL20-DT shows higher tumor expression in KIRC, COAD, HNSC, LUAD, BLCA and STAD. The KIRC box plot shows higher MRPL20-DT RNA expression in tumor versus normal tissue (log2 FC = +0.634, t-test p < 0.001).
This table shows molecular features associated with MRPL20-DT in patient tissues and cancer cell lines. In patient samples, MRPL20-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
